Dr. Sanjeev Redkar is a co-founder, Executive Director and President of Apollomics. Dr. Redkar is mainly responsible for establishing and overseeing the overall strategic planning, business development and management of the Company. He has over 26 years of scientific, managerial and executive experience in hematology and oncology drug discovery and development, especially for small-molecule drugs. Dr. Redkar previously served as a senior vice president for product development at Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) and worked as the manager of process development and manufacturing, senior director of pharmaceutical development, vice president in charge of manufacturing and preclinical development successively at SuperGen, Inc. before its acquisition of Astex Therapeutics Limited.
Dr. Redkar received his Bachelor of Technology degree in chemical engineering from Indian Institute of Technology in India, and he holds a Master of Science degree in chemical engineering and a Ph.D. degree in chemical engineering from University of Colorado, Boulder in the United States. He also obtained a Master of Business Administration degree from St. Mary’s College of California in the United States. Dr. Redkar has authored and co-authored over 25 peer-reviewed scientific articles and co-invented 26 patents that have been issued in the United States. Dr. Redkar serves as Adjunct Faculty and as an Industrial Advisory Board Member at the T.J. Long School of Pharmacy of the University of Pacific. He also serves as a Board Member, Faculty, and Entrepreneur-in-Residence at the Jie Du Center for Entrepreneurship.